<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03722329</url>
  </required_header>
  <id_info>
    <org_study_id>SB12-1001</org_study_id>
    <nct_id>NCT03722329</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic, Safety, Tolerability, Immunogenicity, and Pharmacodynamic Study of SB12 in Healthy Subjects</brief_title>
  <official_title>A Randomised, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, Immunogenicity, and Pharmacodynamics of Eculizumab (SB12, EU Sourced Soliris®, and US Sourced Soliris®) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Bioepis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Bioepis Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate PK, safety, tolerability, immunogenicity, and PD profiles of SB12,
      EU sourced Soliris, and US sourced Soliris in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 13, 2018</start_date>
  <completion_date type="Actual">April 8, 2019</completion_date>
  <primary_completion_date type="Actual">March 29, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Day 1 to Day 64</time_frame>
    <description>Area under the concentration-time curve from time zero to infinity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUClast</measure>
    <time_frame>Day 1 to Day 64</time_frame>
    <description>Area under the concentration-time curve from time zero to the last quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1 to Day 64</time_frame>
    <description>Maximum observed serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 1 to Day 64</time_frame>
    <description>Time to reach Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz</measure>
    <time_frame>Day 1 to Day 64</time_frame>
    <description>Volume of distribution during terminal phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz</measure>
    <time_frame>Day 1 to Day 64</time_frame>
    <description>Terminal rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>Day 1 to Day 64</time_frame>
    <description>Terminal half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance</measure>
    <time_frame>Day 1 to Day 64</time_frame>
    <description>Total body clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%AUCextrap</measure>
    <time_frame>Day 1 to Day 64</time_frame>
    <description>Percentage of AUCinf due to extrapolation from time of last measurable concentration (Tlast) to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Day 1 to Day 64</time_frame>
    <description>Experience at least 1 treatment-emergent adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events</measure>
    <time_frame>Day 1 to Day 64</time_frame>
    <description>Experience at least 1 serious adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ADA</measure>
    <time_frame>Day 1 to Day 64</time_frame>
    <description>Incidence of anti-drug antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence NAb</measure>
    <time_frame>Day 1 to Day 64</time_frame>
    <description>Incidence neutralising antibodies</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SB12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB12 (proposed eculizumab biosimilar)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU Soliris</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EU sourced Soliris (eculizumab)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US Soliris</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>US sourced Soliris (eculizumab)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eculizumab</intervention_name>
    <description>Eculizumab Injection. 300 mg, single dose</description>
    <arm_group_label>EU Soliris</arm_group_label>
    <arm_group_label>SB12</arm_group_label>
    <arm_group_label>US Soliris</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Have a body weight between 70-95 kg and a body mass index between 20.0-29.9 kg/m²

          -  Have systolic blood pressure (SBP) ≤ 140 and ≥ 90 mmHg, diastolic blood pressure (DBP)
             ≤ 95 and ≥ 45 mmHg, and pulse rate ≥ 40 and ≤ 100 beats per minute or assessed as not
             clinically significant

          -  Have physical examination and 12-lead ECG results without clinically significant
             finding at Screening and Day -1 visits

          -  Non-smoker or smoker whose daily smoking does not exceed 10 cigarettes, 3 cigars, or 3
             pipes for at least 30 days prior to Screening visit. Subjects should agree to abstain
             from smoking while resident at the clinical study site.

          -  Willing to receive vaccination against N. meningitidis at least 14 days prior to IP
             administration

          -  Male subjects must be willing to abstain from sexual intercourse or willing to use a
             condom in addition to having their female partner use another form of contraception
             unless their partner is infertile from the time of IP administration until 5 months
             after IP administration

          -  Must be willing and able to comply with scheduled visits, treatment plan, clinical
             laboratory tests, and other study procedures including lifestyle considerations

          -  Have competence in speaking, writing and comprehending the local language where the
             study is conducted

        Exclusion Criteria:

          -  Have a history/presence of clinically significant atopic allergy,
             allergic/hypersensitive reactions, or known or suspected clinically relevant drug
             hypersensitivity to eculizumab or its excipients

          -  Contraindication for IP or non-IP to be used in the study

          -  History of N. meningitidis infection

          -  Known or suspected hereditary or acquired complement deficiency

          -  Clinically significant active infection within 28 days before IP administration

          -  Any systemic or local infection, a known risk for developing sepsis and/or known
             active inflammatory condition

          -  Have previously been exposed to eculizumab (Soliris and its biosimilar)

          -  Previous treatment with a monoclonal antibody or fusion protein within 9 months prior
             to IP administration and/or have an evidence of immunogenicity from previous exposure
             to a monoclonal antibody or fusion protein

          -  Have previously been exposed to an immunosuppressive agent or biological agent (any
             other than a monoclonal antibody or fusion protein) within 120 days prior to IP
             administration

          -  Any of the following abnormal laboratory values at Screening and Day -1 visits:

               1. Serum alanine transaminase and/or aspartate transaminase ≥ 1.5 × ULN

               2. Serum C-reactive protein ≥ 10 mg/L

               3. Serum creatinine &gt; 1.5 × ULN

               4. Whole blood cell count &lt; 3000/mm3, absolute lymphocyte count &lt; 800/mm3, and/or
                  absolute neutrophil count ≤ 1500/mm3

               5. Any other laboratory abnormalities assessed as clinically significant by the
                  Investigator

          -  Positive test result for hepatitis B surface antigen and/or hepatitis B core antibody,
             hepatitis C virus antibody, or human immunodeficiency virus at Screening

          -  Surgery within 90 days prior to IP administration, and/or operation during study
             period

          -  Average intake of alcoholic beverages of more than 21 units/week for males and 14
             units/week for females

          -  Drug abuse or a positive urinary drug screening result

          -  Have any prescription medicine or over-the-counter medicines (except paracetamol) that
             might have an effect on the objectives of the study, within 14 days prior to IP
             administration

          -  Donated &gt;100 mL blood or plasma within 28 days prior to IP administration

          -  Subject directly involved in the conduct of the clinical study

          -  Vulnerable subjects

          -  Pregnant or nursing (lactating) women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainard Fuhr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PAREXEL International GmbH, Early Phase Clinical Unit - Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PAREXEL International GmbH, Early Phase Clinical Unit - Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 24, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

